[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444967":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":38,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University Hospital Heidelberg","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Richard F Schlenk, M.D.","University Hospital Heidelberg, Department of Internal Medicine V, German Cancer Research Center","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Editha Gnutzmann, M.A.","CONTACT","+49 6221 56 36235","editha.gnutzmann@med.uni-heidelberg.de",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"UHHeidelberg","RECRUITING","Heidelberg","Baden-Wurttemberg","69120","Germany","DE",{"type":29,"coordinates":30},"Point",[31,32],8.69079,49.40768,{"lat":32,"lon":31},[35],{"name":36,"role":16,"phone":37,"phoneExt":7,"email":18},"Editha Gnutzmann","+4962215636235",{"type":12,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Prof. Dr. Richard F Schlenk","Head of NCT trials center and Clinical Trials Office Hematology\u002FOncology","100444967","the-myeloid-neoplasms-biology-and-outcome-project-100444967",false,"NCT05074316","The Myeloid Neoplasms Biology and Outcome Project","A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Patients With Myeloid Neoplasms","MyBOP","Inclusion Criteria:\n\n* Suspected or proven diagnosis of Myeloid Neoplasms according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues\n* Age ≥18 years\n* Ability to understand the nature and individual consequences of the registry\n* Written informed consent\n* Subjects who are physically or mentally capable of giving consent\n\nExclusion Criteria:\n\nSevere neurological or psychiatric disorder interfering with the ability to give written informed consent","ALL","18 Years",{"count":52,"type":53},1000,"ESTIMATED","OBSERVATIONAL","The Myeloid Neoplasms Biology and Outcome Project (MyBOP) aims to establish a registry study for patients with myeloid neoplasms. It integrates clinical data, biological samples, socio-demographic information, long-term follow-up and patient reported outcomes in a structured manner for scientific purposes.\n\nThe ultimate benefits are:\n\n1. Improvement of evidence-based clinical management of patients with myeloid neoplasms through better understanding of the course of disease and prognostic and predictive parameters\n2. Direct access to new and personalized treatment approaches through recruitment into clinical studies based on the myeloid neoplasms study platform\n3. Quality assurance of participating centers by evaluating and comparing clinical outcomes and side effects of the MyBOP patients with published data.",[57],"Myeloid Neoplasm",[59,60],"outcome project","registry","2025-03-24",{"date":63,"type":64},"2025-03-25","ACTUAL",{"date":66,"type":64},"2020-03-10",{"date":68,"type":53},"2032-12-31",{"name":5,"class":6},1]